Eli Lilly breaks ground on $3.5B Pennsylvania manufacturing site for obesity meds

Eli Lilly announced a $3.5 billion investment to build a manufacturing facility in Pennsylvania's Lehigh Valley, creating 850 jobs. The site, part of a $50 billion U.S. expansion, will produce obesity treatments like retatrutide, with operations expected to begin by 2031. According to officials, this is the largest life science investment in Pennsylvania history.

Jefferies raised its price target for Eli Lilly (LLY) to $1,700, citing its strong economic moat. The Nasdaq and S&P 500 fell sharply last Thursday due to AI spending concerns and political shifts. Analysts from Morgan Stanley and UBS view the selloff as overdone, while Goldman Sachs notes potential data center restrictions.

Eli Lilly and Company has begun construction on a $3.5 billion facility in Pennsylvania's Lehigh Valley to manufacture next-generation obesity medicines, including retatrutide. The site will create 850 high-wage jobs and 2,000 construction jobs, marking the latest of 10 new U.S. sites since 2020. The company plans to invest significantly in advanced manufacturing and community initiatives.

Eli Lilly (LLY) began construction on a $3.5B facility in Pennsylvania to produce obesity treatments, including retatrutide. The site will create 850 jobs and is part of a $50B U.S. expansion. Lilly also announced community initiatives and sustainability goals for the project, expected to open in 2031.

A study presented at the American College of Rheumatology meeting and published in the New England Journal of Medicine found that retatrutide, a new weight-loss drug developed by Eli Lilly, may also reduce knee pain in obese patients with osteoarthritis. The trials involved over 1,000 participants taking varying doses of the drug or a placebo.

Eli Lilly (NYSE:LLY) shares rose after positive phase 3 trial results for retatrutide in treating knee osteoarthritis pain and weight loss. The company also partnered with Hims & Hers to expand access to GLP-1 drugs. Additionally, Lilly reported that Foundayo reduced sleep apnea severity, with FDA submission planned. Q3 revenue grew 39% to $24.4B, and earnings per share increased 16% to $7.22. Jefferies raised its price target to $1,700.